Roche blood test could help 'personalize' cancer immunotherapy

[D.ap]

Reuters) - A new blood test from Roche and Foundation Medicine has shown it can accurately measure the number of mutations within a tumor, potentially helping to predict which patients may respond best to some immunotherapies.

Initial data on Roche's test aimed at determining tumor mutational burden, or TMB, was released on Friday at the European Society for Medical Oncology (ESMO) congress in Madrid.

Immunotherapies such as Roche's Tecentriq, Merck's Keytruda and Bristol-Myers Squibb's Opdivo have offered fresh hope to people with deadly cancers, but they only work in a fraction of patients.


https://www.google.com/amp/s/mobile.reu ... SKCN1BI30F